Welcome to the Valproate semisodium (Belvo GR)▼ information page. The materials below have been created to help Healthcare Professionals understand the important safety information associated with Valproate. You can view and download the information materials by clicking on the links below.
You should visit this page each time to ensure you have the latest information.
For any further information about Valproate semisodium (Belvo GR) you can contact our Medical Information
department via email drugsafety@consilienthealth.com or telephone +44 (0)203 751 1888 (option 1).
Belvo gastro-resistant tablet Patient Information Leaflet - PIL
Valproate Summary of Product Characteristics - SPC
Valproate Female Patient Guide GB & NI – May 2025 (aRMM)
Valproate Male Patient Guide GB & NI – May 2025 (aRMM)
Valproate Patient Card GB & NI – May 2025 (aRMM)
Valproate Female ARAF GB & NI – May 2025 (aRMM)
Annual Risk Acknowledgement Form for Female Patients
This form is for female patients aged under 55 years to complete with their specialist. Valproate should only be used in this group when two specialists have confirmed that other treatment options are not suitable. If you are able to become pregnant, you must also meet the requirements of the valproate Pregnancy Prevention Programme (Prevent).
Your specialist should review your treatment regularly and complete this from with you at least once a year. This is to ensure you understand and acknowledge the risks of taking valproate during pregnancy and the importance of avoiding pregnancy while using this medicine.
Valproate Risk Acknowledgement Form for Males GB & NI – May 2025 (aRMM)
Risk Acknowledgement Form For Male Patients
This form is for male patients aged under 55 years to complete with their specialist when starting valproate. Valproate should not be initiated in this group unless two specialists have confirmed that other treatment approaches are unsuitable or that considerations around fertility risk do not apply.
Your specialist should discuss the relevant risks and ensure that the form is completed as part of the initiation process.
Valproate HCP Guide GB & NI – May 2025 (aRMM)
Valproate DHPC aRMM Cover Letter for HCPs (non-dispensing) GB & NI – May 2025
Valproate DHPC aRMM Cover Letter for Pharmacists GB & NI – May 2025
Valproate A4 Pharmacy Poster GB & NI 2023 (aRMM)
CNIL data protection information for French HCPs (link)
Information Note specific to the AVALON project – SNDS English Version
Information Note specific to the AVALON project – SNDS French Version
Code No: UK-CH-1819
Date of Preparation: May 2026